Signaling through the epidermal growth factor receptor (EGFR) has been primarily implicated in the growth of epithelial cells including keratinocytes. However, the mechanism by which EGFR stimulation promotes keratinocyte cell growth is poorly understood. Here we report that human keratinocytes undergo apoptosis when incubated with the blocking EGFR monoclonal antibody 225 IgG, or PD153035, a highly speci®c EGFR tyrosine kinase inhibitor. Endogenous mRNA and protein levels of Bcl-X L , a member the Bcl-2 family which suppresses apoptosis, were speci®cally inhibited by EGFR blockade. Furthermore, stimulation of EGFR signaling through two natural ligands, transforming growth factor (TGF)-a and epidermal growth factor (EGF), increased the expression of Bcl-X L in quiescent keratinocytes and HaCaT cells. Finally, ectopic expression of Bcl-X L in HaCaT cells increased survival after EGFR blockade when compared to untransfected cells or HaCaT keratinocytes transfected with empty vector. These results suggest that the anti-apoptotic protein Bcl-X L plays an important role in the maintenance of keratinocyte survival in response to EGFR signaling.
Keratinocytes appear to play an active role in cutaneous immunoregulation and growth control via the production of a number of cytokines and growth factors (Elder, 1995) . Prominent among them are several members of the EGF family, including transforming growth factor (TGF)-a, amphiregulin (AR), and heparin-binding EGF-like growth factor (HB-EGF) (Coey et al., 1987; Cook et al., 1991; Hashimoto et al., 1994) . It has been suggested that these factors regulate growth and dierentiation of normal keratinocytes by serving as autocrine and/or juxtacrine ligands for the EGF receptor (EGFR, ErbB-1) (Barnard et al., 1994) . However, three other receptors have been identi®ed as belonging to the same subfamily of tyrosine kinases as ErbB-1 (termed ErbB-2, -3, and -4), and at least two of these, ErbB-2 and -3, are expressed by keratinocytes (Marikovsky et al., 1995; Poumay and Pittelkow, 1995; Xian et al., 1997 ). An additional family of EGF-related growth factors, termed neu dierentiation factors (NDFs), further adds to the complexity of the ErbB signaling system. NDFs are expressed from at least two genes as a number of isoforms generated by alternate splicing (Carraway et al., 1997) . Initially, it was thought that NDF was the speci®c ligand for ErbB-2 (Holmes et al., 1992) . However, through much eort it is now clear that a variety of asymmetric ErbB heterodimers capable of binding ligands of both the EGF and NDF families can form, including ErbB-1/-2, ErbB-1/-3, and ErbB-2/-3 (Alimandi et al., 1997; Graus Porta et al., 1997; Tzahar et al., 1996) . Despite these emerging complexities, at least ®ve lines of evidence suggest that ErbB-1 is responsible for the bulk of autocrine keratinocyte activation through the ErbB system. First, highly speci®c anti-EGFR monoclonal antibodies (mAb) abrogate proliferation and ligand-induced tyrosine phosphorylation of a 170 kDa ErbB-1-immunoreactive protein in normal human keratinocytes (Klein et al., 1992) . Second, while NDF is expressed in the dermis in vivo, and in cultured keratinocytes in vitro, it is not mitogenic for keratinocytes in culture (Danilenko et al., 1995; Poumay and Pittelkow, 1995) . Third, keratinocytes do not detectably express ErbB-4 (Marikovsky et al., 1995) . Fourth, ErbB-3 is essentially inactive catalytically (Guy et al., 1994) . Finally, ErbB-2 has no known ligand and appears to respond catalytically to ligand only as a heterodimer (Graus Porta et al., 1997) .
Activation of growth factor receptors transmit signals involved in mitogenesis but also in cellular dierentiation and survival. For example, stimulation of IL-3 or erythropoietin receptors provides both proliferation and survival signals to hematopoietic precursors (Boyer et al., 1992; Koury and Bondurant, 1988; Silva et al., 1996) . Similarly, signaling through EGFR has been shown to promote cell cycle progression, dierentiation and survival of epithelial cells (Merlo et al., 1995; Wu et al., 1995) . Blockade of EGFR signaling on benign and tumor epithelial cell lines with neutralizing antibodies directed against this receptor resulted in a cytostatic eect with or without cell cycle arrest [ (Wu et al., 1995) , and references therein. In certain tumor cell lines, however, treatment with anti-EGFR antibodies induced apoptotic cell death suggesting that EGF stimulation is involved in the regulation of cell survival (Wu et al., 1995) . However, the signi®cance of EGF-induced survival for the overall function of EGFR remains unclear, as does the mechanism by which EGFR activation promotes cell survival.
Apoptosis, a morphologically distinguished form of programmed cell death, is critical not only during development and tissue homeostasis but also in the pathogenesis of cancer and a variety of diseases (Thompson, 1995; Vaux and Strasser, 1996) . Several regulatory components of the apoptotic pathway have been identi®ed in various organisms including man (Evan et al., 1996) . The products of several members of the Bcl-2 family of proteins including Bcl-2, Bcl-X L , Mcl-1, A1, Bcl-w share conserved regions termed Bcl-2 homology (BH) domains 1, 2, 3 and 4 and function by repressing apoptosis (Chittenden et al., 1995; Yin et al., 1994) . One member of this family, Bcl-X L , is expressed in many embryonic and adult tissues, and its importance has been revealed by analysis of mutant mice de®cient in Bcl-X L (Gonzales-Garcia et al., 1994; Motoyama et al., 1995) . Unlike Bcl-2 itself, Bcl-X L is expressed at high levels in normal adult human keratinocytes (Wrone-Smith et al., 1995) . Given the important role that Bcl-X L plays in the regulation of apoptosis and its expression in the cell type of interest, we sought to determine if the EGFR pathway could regulate keratinocyte survival through Bcl-X L .
In order to examine the eect of EGFR blockade on keratinocyte cell growth, HaCaT cells were incubated with PD153035, a highly selective inhibitor of the EGFR tyrosine kinase. (Fry et al., 1994) HaCaT is a spontaneously-immortalized, nontumorigenic keratinocyte cell line derived from normal-appearing back skin of a 62 year old male (Boukamp et al., 1988) . Although this line carries mutations in both p53 alleles (Lehman et al., 1993) and displays a transformed phenotype in vitro, it is capable of extensive dierentiation upon transplantation to nude mice (Boukamp et al., 1988) . PD153035 and other low molecular weight inhibitors of ErbB tyrosine kinase activity are thought to owe their selectivity to interactions with structures in the kinase domain unique to the ErbB family (Fry et al., 1997; Hanks and Hunter, 1995) . Thus, PD153035 displayed 20-fold higher inhibitory potency against ErbB-2 than against any of ®ve other tyrosine kinases (Fry et al., 1994) . While its selectivity for ErbB-1 within the ErbB family has not been reported in detail, PD153035 was 10 6 times more potent against ErbB-1 (as anity-puri®ed receptors from A431 cells, IC 50 =29 pM) than against ErbB-2 (as overexpressed soluble cytoplasmic domains, IC 50 =2.3 mM) (Fry et al., 1994) . Nanomolar concentrations of PD153035 markedly inhibited HaCaT cell growth, with an IC 50 of less than 30 nM (Figure 1a ). At these concentrations, PD153035 had no eect on tyrosine phosphorylation by ErbB-2 cytoplasmic domains (Fry et al., 1994) . In parallel experiments, HaCaT cells were incubated with increasing concentrations of 225 IgG, an anti-EGFR monoclonal antibody which blocks ligand binding without inducing tyrosine phosphorylation (Sunada et al., 1986) . Treatment with puri®ed 225 IgG but not with control IgG signi®cantly inhibited the growth of HaCaT cells (Figure 1b ). However, inhibition was not complete, despite an antibody concentration more than ®ve times that required for EGF to saturate EGFR in normal keratinocytes (1 mg/ml 225 IgG=6.6 nM, vs the EGFRsaturating concentration of 1.2 nM EGF (Nickolo et al., 1989) ). Taken together, these results strongly suggested that autocrine ErbB activation by one or more secreted EGF-like factor(s) is required for the proliferation or survival of HaCaT cells in culture. While the incomplete response to 225 IgG raises the question of participation of other signal transduction pathways, the profound and complete response to PD153035 strongly suggests that one or more ErbB family members must be involved. As discussed earlier, at least ®ve lines of evidence suggest that the relevant ErbB signaling complex must contain ErbB-1, either as a homodimer or complexed with ErbB-2 or ErbB-3.
To determine if the eect on cell growth mediated by EGFR blockade was due to an increase in the rate of cell death, we determined the level of apoptosis in HaCaT cells treated with PD153035. PD153035 treatment induced marked apoptosis, as assessed by the TUNEL assay (Surh and Sprent, 1994) and the appearance of a cell population with a sub-G0 DNA peak (Nicoletti et al., 1991) (Figure 2a) . To determine the relevance of these observations to normal keratinocytes, we tested the eect of the PD153035 on keratinocyte outgrowth from human skin explants, an in vitro model originally developed for porcine skin (Hebda, 1988) . As we observed with the HaCaT cell line, incubation of outgrowth cultures with the EGFR tyrosine kinase inhibitor induced apoptosis as determined by the appearance of TUNEL-positive keratinocytes (Figure 2b ). These results suggest that EGFR signaling promotes keratinocyte survival by inhibiting apoptosis.
To determine whether EGFR signaling regulates the expression of Bcl-X L , HaCaT cells were incubated with TGF-a or EGF, two physiological ligands of the EGFR known to rapidly induce EGFR tyrosine phosphorylation in keratinocytes (Klein et al., 1992) . Both ligands induced the expression of Bcl-X L and HB-EGF mRNAs, the latter of which is known to be regulated by EGFR signaling (Hashimoto et al., 1994) (Figure 3) . Signi®cantly, incubation with either the blocking EGFR mAb 225 IgG (Figure 3a) or the EGFR-TK inhibitor PD153035 (Figures 3b and 3c) inhibited induction of both Bcl-X L and HB-EGF to below background levels. PD153240, a biologicallyinactive congener of PD153035, had no eect ( Figure  3b ). Suggestive of a common mechanism of inhibition, the IC 50 values and maximal eects of PD153035 were very similar for both responses (Figure 3c ). These events were re¯ected at the protein level, as incubation of HaCaT cells with EGF markedly increased the amount of immunoreactive of Bcl-X L protein at 24 and 48 h after treatment (Figure 3c ). In contrast to these results, bcl-2 was not detectably expressed by keratinocytes, and expression was not induced by EGF treatment (data not shown).
To determine whether Bcl-X L plays a functional role in EGFR-mediated keratinocyte survival, we overexpressed this protein ectopically and asked whether it could promote cell survival in HaCaT cells deprived of ErbB signaling by PD153035 treatment. HaCaT cells were transfected with an expression construct produ- 2 ) were placed on microscope slides, allowed to attach for 15 min and incubated in RPMI 1640 medium containing 1% FBS, EGF (5 ng/ ml) and TGF-beta (2 ng/ml) as previously described for porcine skin (Hebda, 1988) . After 5 days, epidermal outgrowth samples were incubated with DMSO or 0.3 mM PD153035 for 24 ± 72 h and assessed for DNA fragmentation using the in situ TUNEL assay as described above. The white line across the lower portion of each image indicates the edge of the tissue explant from which keratinocytes have migrated cing Bcl-X L and a clone of HaCaT cells overexpressing high levels of Bcl-X L was isolated (Figure 4a) . These cells were then challenged with PD153035 in parallel with vector-transfected controls. As shown in Figure  4b , vector-transfected controls and nontransfected cells displayed very similar, dose-dependent reductions in cell number in response to EGFR blockade, whereas expression of Bcl-X L signi®cantly protected the cells from this eect. Protection was observed at all doses tested, but was never complete.
The results presented herein indicate that ErbB signaling regulates keratinocyte survival by providing signals that inhibit apoptotic cell death, and strongly suggest that ErbB-1 plays a major role in this process by increasing expression of Bcl-X L . This phenomenon is not unique to keratinocytes in that EGFR activation has been shown to protect neurons, mammary epithelial cells, colon carcinoma cells and ovarian granulosa cells from programmed cell death (Merlo et al., 1995; Tilly et al., 1992; Wu et al., 1995) . In (Elder et al., 1991) . At 40% con¯uence keratinocytes were rendered quiescent by deprivation of growth factors for 48 h, then treated with EGF or TGF-a as described (Klein et al., 1992) . Thirty min prior to growth factor treatment cultures were pretreated with either 225 IgG, the EGFR tyrosine kinase inhibitor PD153035 or its inactive congener PD153240. Total RNA was prepared using RNAzol (Tel-Test, Friendswood, TX) according to the manufacturers instructions. Thirty to forty micrograms of total RNA was electrophoretically separated on 1% formaldehyde-agarose gels and transferred to Zeta-probe nylon membranes (Bio-Rad, Richmond, CA) and hybridized against 32 P-labeled Bcl-X L cDNA probe as previously described (Elder et al., 1990) . Heparin-binding EGF-like growth factor (HB-EGF) is included in Figure 3a (Nass et al., 1996) . Moreover, Rodeck and colleagues have recently reported results similar to our own in keratinocytes (Rodeck et al., 1997a) . Our studies are the ®rst to demonstrate a functional role for Bcl-X L in EGFR-dependent KC survival. However, we found that protection from PD153035-induced apoptosis was never complete (Figure 4 ). Rodeck and colleagues reported a similar result, in that keratinocyte apoptosis developed only gradually after mAb-mediated blockade of ErbB-1 signaling, becoming detectable only after 4 to 5 days of mAb treatment (Rodeck et al., 1997b) . These ®ndings suggest at least three possibilities: (i) that loss of ErbB signaling triggers multiple downstream cell death pathways, only some of which can be blocked by Bcl-X L ; (ii) that Bcl-X L exerts only a modulatory or stochastic eect on a ®nal common pathway of cell death, rather than an all-or-nothing eect; or (iii) that the ErbB pathway interacts with other signaling systems to maintain cell survival. Rodeck's ®nding that anti-ErbB-1-induced apoptosis was dramatically increased by subsequent trypsinization (Rodeck et al., 1997b) favors the third possibility, and suggests that cell contacts provide strong survival signals to keratinocytes. In fact, deprivation of cell-substratum contact has been shown to induce dramatic apoptosis in keratinocytes, accompanied by reduced expression of Bcl-X L (Frisch and Francis, 1994; Mitta et al., 1997) .
Multiple ErbB ligands as well as ErbB-1 are upregulated during the early phases of wound healing and in psoriasis, a disease which has been likened to dysregulated wound healing (Cook et al., 1991; Elder, 1994; Gottlieb et al., 1992; Nanney et al., 1986; Stoll et al., 1997; Stoscheck et al., 1992; Wenczak et al., 1992) . Bcl-X L has been shown to be strongly upregulated in psoriatic skin, whereas bcl-2 was essentially undetectable (Wrone-Smith et al., 1995) . We suggest that the elevation of Bcl-X L expression in psoriasis is yet another manifestation of excessive ErbB signaling in that disease. Keratinocyte proliferation and invasiveness is greatly increased in both psoriasis and wound healing, and it would seem bene®cial for the organism to ensure that this aggressive cellular behavior be subjected to multiple levels of control. The regulation of Bcl-X L through EGFR appears relevant not only to these settings, but also to cancer. Thus, EGF and TGF-a regulate the expression of Bcl-X L in mouse mammary tumor cells, as mentioned earlier (Nass et al., 1996) . ErbB-2 signaling is markedly increased in many breast carcinoma cell lines, resulting in a state of growth factor-independent cell survival and proliferation (Ram et al., 1996) . It remains to be determined whether hyperactivation of ErbB-2 promotes the survival of breast carcinoma cells through BcL-x L . Increased autocrine signaling is a feature of many epithelial malignancies (Lang and Burgess, 1990) , and the ErbB system has been implicated in several of the most aggressive, including gastric (Naef et al., 1996) , lung (Rachwal et al., 1995) , and pancreatic (Kobrin et al., 1994) carcinomas. It will be important to determine the extent to which the ErbB-Bcl-X L axis serves as a general mechanism for inappropriately maintaining the survival of tumor cells across the spectrum of epithelial cancers, which in aggregate account for 90% of all invasive malignancies (DeGuire et al., 1994) . 
